The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran
- 20 Downloads
Moderate to high risk medical inpatients are at increased risk of Venous Thromboembolism (VTE). The present study aims to investigate the cost-effectiveness and cost-utility of using Enoxaparin compared to Heparin in VTE prophylaxis in medical inpatients, from Iranian payer’s perspective.
Decision tree modeling technique was used to evaluate cost-effectiveness and cost-utility of the compared interventions. The main considered outcomes were Life Years Gained (LYG) for Cost-Effectiveness Analysis (CEA) and Quality-Adjusted Life Years (QALY) for Cost-Utility Analysis (CUA). Costs and consequences of the interventions were evaluated for a three-month period and reported as Incremental Cost-Effectiveness Ratios (ICERs). One-way and Probabilistic Sensitivity Analysis (PSA) were conducted to evaluate the robustness of the model due to uncertainty in the input data.
In base case scenario (i.e. public tariff), incremental cost was $10.32, and incremental QALY and incremental LYG were 0.0001 and 0.0002 per patients respectively. Base case ICERs were 60,376 USD/QALY and 71,077 USD/LYG per patient. The results of the sensitivity analysis showed the robustness of the model.
As the estimated ICER per QALY is more than three times the reported Gross Domestic Product (GDP) per capita by world bank for Iran in 2017 ($5415), the use of Enoxaparin for VTE prophylaxis in medical in patients doesn’t seem to be a cost-effective intervention compared to the use of Heparin in Iran.
KeywordsEconomic evaluation Enoxaparin Heparin Venous thromboembolism Medical inpatients
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Blann A. Deep vein thrombosis and pulmonary embolism: a guide for practitioners: M&K Update Ltd. Cumbria. 2015.Google Scholar
- 3.Piazza G, Hohlfelder B, Goldhaber SZ. Handbook for Venous Thromboembolism: Springer; 2015.Google Scholar
- 4.Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23_suppl_1):I-9–I-16.Google Scholar
- 7.Sharif-Kashani B, Mohebi-Nejad A, Abooturabi S-M. Estimated prevalence of venous thromboembolism in Iran: prophylaxis still an unmet challenge. Tanaffos. 2015;14(1):27–33.Google Scholar
- 9.Wells G, Kelly S, Elliot J, Carrier M, Geerts W, Lee AYY, et al. Low molecular weight heparin and unfractionated heparin for the prevention of venous thromboembolic in medical and non-orthopedic surgical patients: clinical review [Inernet]. Ottawa: Cardiovascular Research Methods Center, University of Ottawa Heart Institute (CRMC-UOHI); Drug Safety and Effectiveness Network (DSEN); 2016. Available at: http://www.ottawaheart.ca/document/low-molecular-weight-heparin-and-unfractionated-heparin-prevention-venous-thromboembolic. Accessed 10 May 2018.
- 12.Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83(1):14–9.CrossRefGoogle Scholar
- 15.The central Bank of Iran (CBI); Exchange Rates. 2018. Available at: http://www.cbi.ir/ExRates_fa.aspx. Accessed Nov14,2018.
- 19.Ghandehari K, Izadi-Mood Z. Khorasan stroke registry: analysis of 1392 stroke patients. Arch Iran Med. 2007;10(3):327–34.Google Scholar
- 21.Ministry of Health and Medical Education; Tariff Book of Health Services.3rded.2017.Available at: http://ruv.behdasht.gov.ir/index.aspx. Accessed 20 Aug 2018.
- 22.Iran Food and Drug Administration (IFDA); National Formulary of Iran (NFI). 2018. Available at: http://irc.fda.gov.ir/nfi. Accessed 7 Aug 2018.
- 26.The World Bank; GDP per capita. 2018. Availabe at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 28 Nov 2018.
- 28.McGarry LJ, Thompson D, Weinstein MC, Goldhaber SZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care. 2004;10(9):632–42.Google Scholar